Life Sciences Investors Forum 2022

The Life Sciences Investors Forum is supported by FEDER funds, thanks en mieux.

Last Week, the third edition of the Life Sciences Investor Forum led by Bridge to Health, Noshaq and EKLO took place in a hybrid version.

During this event, 6 Liège-based companies active in the Life Sciences sector presented their development projects to Belgian and international investors.

The 2022 edition was :  

  • 6 high level companies  
  • 107 M€ of financial needs
  • 80 investors and companies specialized in Life Sciences behind their screens
  • An additional opportunity to highlight the expertise, excellence and quality of Liège’s Life Sciences companies

The speakers :

We were fortunate to have CEOs from 6 promising companies present their activities and explain the ambitions behind the amounts they seek.

  • Wim Vos, RADIOMICS : Spin-off or the University of Maastricht, based in Liège. The Company develops AI models and algorithms to translate medical imaging in oncology into useful information to pharma companies to develop new drugs or to clinicians to propose personalized treatments.
  • Pierre Close & Francesca Rapino, Theratrame : Spin-off of the University of Liege. The Company is active in the preclinical development of new molecules for the treatment of different kind of cancers.
  • Pierre Douette, Cardiatis : The company develops an innovative and unique platform of endovascular prostheses for the treatment of aortic diseases with a specific focus on aortic dissection.
  • Fabrice Giacomelli, Nucleis : Spin-off of the University of Liege. Nuclieis is a CMO, i.e.: manufacturer of radiopharmeutical products used by hospitals and pharma companies.
  • Fabian Suarez, Man & Sciences : The Company develops a neurostimulation device for the treatment of headaches disorders with a focus on chronic cluster heaches.
  • Olivier Delporte, Miracor : Company founded in Austria, based in Liege. The Company develops a medical equipment to improve coronary microcirculation & reduce infarct size in STEMI patients (= infarctus du myocarde).

Liège, a Belgian hotspot for the Life Sciences sector.

In a decade, Liege has become one of the most attractive locations for life sciences companies in Belgium. The region is home to more than 140 companies, operating in a comprehensive, innovation-driven ecosystem.

Today, Liège represents :

  • 140 companies
  • more than 15 thousand direct and indirect jobs
  • 30 thousand square meters of state of the art infrastructure
  • In 2021, the ecosystem has created or attracted 10 new companies
  • In 2021, more that 300 M€ were raised (deals and exits excluded)

Would you like to know more about EKLO’s support for companies active in the Life Sciences sector ?

The Life Sciences Investors Forum is supported by FEDER funds, thanks en mieux

Rejoignez la communauté d’EKLO ! LinkedInFacebookTwitter

Laisser un commentaire